Targeting protein–protein interactions for cancer therapy

[1]  T. Shinohara,et al.  [In-vivo activation of the p53 pathway by small-molecule antagonists of MDM2]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[2]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[3]  Shaomeng Wang,et al.  Structure-based design of potent, conformationally constrained Smac mimetics. , 2004, Journal of the American Chemical Society.

[4]  David C Fry,et al.  NMR structure of a complex between MDM2 and a small molecule inhibitor , 2004, Journal of biomolecular NMR.

[5]  Alexander D. MacKerell,et al.  Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. , 2004, Journal of medicinal chemistry.

[6]  Saul H Rosenberg,et al.  Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. , 2004, Journal of medicinal chemistry.

[7]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[8]  A. Hamilton,et al.  Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein. , 2004, Bioorganic & medicinal chemistry letters.

[9]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[10]  John Calvin Reed,et al.  Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. , 2003, Cancer research.

[11]  Michael B. Yaffe,et al.  The Molecular Basis for Phosphodependent Substrate Targeting and Regulation of Plks by the Polo-Box Domain , 2003, Cell.

[12]  A. D. Buss,et al.  Identification of Chelerythrine as an Inhibitor of BclXL Function* , 2003, Journal of Biological Chemistry.

[13]  T. Berg.  Modulation of protein-protein interactions with small organic molecules. , 2003, Angewandte Chemie.

[14]  John Kuriyan,et al.  A reinterpretation of the dimerization interface of the N‐terminal Domains of STATs , 2003, Protein science : a publication of the Protein Society.

[15]  P. Chène.  Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.

[16]  S. Elledge,et al.  Structure of the Cul1–Rbx1–Skp1–F boxSkp2 SCF ubiquitin ligase complex , 2002, Nature.

[17]  H. Dyson,et al.  Structural basis for Hif-1α/CBP recognition in the cellular hypoxic response , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Toogood.  Inhibition of protein-protein association by small molecules: approaches and progress. , 2002, Journal of medicinal chemistry.

[19]  Martin Lackmann,et al.  Crystal structure of an Eph receptor–ephrin complex , 2001, Nature.

[20]  I. Enyedy,et al.  Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. , 2001, Journal of medicinal chemistry.

[21]  J J Hill,et al.  Biophysical characterization of recombinant human Bcl-2 and its interactions with an inhibitory ligand, antimycin A. , 2001, Biochemistry.

[22]  T. Mitchison,et al.  Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL , 2001, Nature Cell Biology.

[23]  Stephen F. Betz,et al.  Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain , 2000, Nature.

[24]  T. A. Graham,et al.  Crystal Structure of a β-Catenin/Tcf Complex , 2000, Cell.

[25]  David J. Weber,et al.  Structure of the negative regulatory domain of p53 bound to S100B(ββ) , 2000, Nature Structural Biology.

[26]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  T. Nakashima,et al.  Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity. , 2000, Cancer research.

[28]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[29]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[30]  T C Warren,et al.  Crystal structures of the human p56lck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution. , 1996, Journal of molecular biology.

[31]  A. Wittinghofer,et al.  The 2.2 Å crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with RaplA and a GTP analogue , 1995, Nature.

[32]  D. Fry,et al.  Solution structure of the Ras-binding domain of c-Raf-1 and identification of its Ras interaction surface. , 1995, Biochemistry.

[33]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[34]  Thomas Rawson,et al.  From Peptide to Non-Peptide. 2. The de Novo Design of Potent, Non-peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold , 1994 .

[35]  John W. Bean,et al.  Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide , 1993 .

[36]  L. Vassilev,et al.  Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects. , 2005, Methods in enzymology.

[37]  P. S. Kim,et al.  Structure of the Bcr-Abl oncoprotein oligomerization domain , 2002, Nature Structural Biology.

[38]  T. A. Graham,et al.  Crystal structure of a beta-catenin/Tcf complex. , 2000, Cell.

[39]  Gisbert Schneider,et al.  Mapping of proteinase active sites by projection of surface-derived correlation vectors , 1999, J. Comput. Chem..